NCT02263495 - Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

December 19, 2014

Primary Completion Date

May 11, 2017

Study Completion Date

June 17, 2019

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Paclitaxel

175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration

DRUG

Eribulin

1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)

DRUG

Gemcitabine

PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins

Trial Locations (2)

Samsung Medical Center, Seoul

Asan Medical Center, Seoul